Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.
Tapan M. Kadia
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Elias Jabbour
No relevant relationships to disclose
Alessandra Ferrajoli
No relevant relationships to disclose
Srdan Verstovsek
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Naveen Pemmaraju
No relevant relationships to disclose
Naval Guastad Daver
No relevant relationships to disclose
Marina Konopleva
No relevant relationships to disclose
Xuemei Wang
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose